106 research outputs found
Experiences with the GENE-AUTO Code Generator in the Aerospace Industry
International audienceThis paper gives an overview of the most recent experimentations that Astrium and Airbus conducted with the GENE AUTO code generator during 2009. GENE-AUTO is an open source automatic and qualifiable C code generator taking as input Simulink ® /Stateflow ® and Scilab/Scicos models. It was developed in the context of an ITEA European project that ended in December 2008 (www.geneauto.org). The GENE-AUTO toolset is currently maintained by its developers and evaluated for industrial usage by several end-users. This paper presents the case studies that we used for evaluation purposes, explains the organisation between the users and technology providers with respect to the toolset maintenance and summarizes the experimentation results
Automated verification of shape and size properties via separation logic.
Despite their popularity and importance, pointer-based programs remain a major challenge for program verification. In this paper, we propose an automated verification system that is concise, precise and expressive for ensuring the safety of pointer-based programs. Our approach uses user-definable shape predicates to allow programmers to describe a wide range of data structures with their associated size properties. To support automatic verification, we design a new entailment checking procedure that can handle well-founded inductive predicates using unfold/fold reasoning. We have proven the soundness and termination of our verification system, and have built a prototype system
Comment on:The sFlt-1 to PlGF ratio in pregnant women with rheumatoid arthritis: impact of disease activity and sulfasalazine use. Reply
The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients
Compiler-Enhanced Incremental Checkpointing for OpenMP Applications
As modern supercomputing systems reach the peta-flop performance range, they grow in both size and complexity. This makes them increasingly vulnerable to failures from a variety of causes. Checkpointing is a popular technique for tolerating such failures, enabling applications to periodically save their state and restart computation after a failure. Although a variety of automated system-level checkpointing solutions are currently available to HPC users, manual application-level checkpointing remains more popular due to its superior performance. This paper improves performance of automated checkpointing via a compiler analysis for incremental checkpointing. This analysis, which works with both sequential and OpenMP applications, reduces checkpoint sizes by as much as 80% and enables asynchronous checkpointing
Accurate prediction of total PlGF (Placental growth factor) from free PlGF and sFlt-1 (Soluble Fms-Like tyrosine kinase-1):Evidence for markedly elevated PlGF levels in women with acute fatty liver of pregnancy
Tumor Necrosis Factor Inhibitor Use Increases Birthweight in Pregnant Women With Rheumatoid Arthritis Independently of the Soluble Fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio
BACKGROUND: To study whether the use of TNF (tumor necrosis factor) inhibitors (TNFi) by pregnant women with rheumatoid arthritis affects sFlt-1 (soluble Fms-like tyrosine kinase-1), PlGF (placental growth factor), or their impact on birthweight. METHODS AND RESULTS: sFlt-1 and PlGF were measured in all trimesters of pregnancy in the Preconception Counseling in Active Rheumatoid Arthritis study and were compared according to the use of TNFi. The association of sFlt-1 and PlGF with birthweight in relation to TNFi was determined. The study included 158 women, of whom 52.5% used TNFi during pregnancy. Both sFlt-1 and PlGF increased during pregnancy, whereas their ratio declined. Taking into consideration the trimester-related variation in levels of sFlt-1 and PlGF, after correction for relevant confounders, the sFlt-1/PlGF ratio was not significantly different between patients who did or did not use TNFi (sFlt-1/PlGF ratio in the second trimester compared with the first trimester: estimated change 8.17 [95% CI, 2.54-26.29], P=0.79; sFlt-1/PlGF ratio in the third trimester compared with the first trimester: estimated change 6.25 [95% CI, 1.73-22.50], P=0.25). In women who did not use TNFi, birthweight was significantly lower (3180 versus 3302 g; P=0.03), and sFlt-1 displayed a negative correlation with birthweight (r=-0.462, P<0.001) and birthweight percentile (r=-0.332, P=0.008). In TNFi users, these correlations were absent. CONCLUSIONS: TNF inhibitor use increases birthweight in pregnant women with rheumatoid arthritis independently of the sFlt-1/PlGF ratio. REGISTRATION: http://clinicaltrials.gov. Unique identifier: NCT01345071.</p
- …